GlassScriptPhysician profile
Amber C Vasold
NPI 1013389683
$9,108.96
in general payments reported to CMS, 2019-2025
37 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,820 · 2022: $1,919 · 2023: $2,260 · 2024: $1,822 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,369.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,190.07 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,173.78 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,130.02 | 2021-2025 | |
| Amgen INC. | $1,006.62 | 2021-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $749.75 | 2021-2025 | |
| Glaxosmithkline, LLC. | $727.40 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $712.60 | 2021-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $320.22 | 2021-2023 | Xarelto |
| Amarin Pharma, INC. | $234.12 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $214.11 | 2022 | |
| Silk Road Medical, INC. | $178.18 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Exact Sciences Corporation | $176.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $167.58 | 2021-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.76 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $146.53 | 2022-2024 | Verquvo, Belsomra, Steglatro |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Vasold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.